Drugs / 6MHP
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02382549 | Apr 2016 → Feb 2022 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04364230 | Sep 2020 → Mar 2024 | uveal melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT03617328 | Nov 2018 → Jan 2024 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT02515227 | Oct 2016 → Mar 2020 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 1/2 | NCT02425306 | May 2015 → Aug 2017 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 1/2 | NCT02385669 | Apr 2015 → Sep 2019 | melanoma | Craig L Slingluff, Jr | Terminated | No outcome recorded |
| Phase 1/2 | NCT00089219 | Jul 2003 → May 2006 | cutaneous melanoma, ocular melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6MHP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02425306 ↗ |
| Modality | Vaccine | “safety and immunogenicity of a vaccine comprised of six melanoma helper peptides” PMID 18809608 ↗ Sep 2008 |
| Route | Subcutaneous | “All peptide vaccines are administered intradermally and subcutaneously.” NCT02382549 ↗ |